Hafez Halawani, MD
Hematology & Oncology · Alexandria, LANPI 1023008372
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,361 of the $17,649 with a category attached, or 70.0%. 39 manufacturers reported payments, led by Sanofi at 41.3% of the total. 2025 is the largest year on record at $8,421, more than ten times the $625 reported in 2019.
Across 198 payments — averaging $89.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$7K
- E.r. Squibb & Sons, L.L.C.$3K
- AstraZeneca$2K
- Novartis$2K
- Astellas Pharma US Inc$620
- Merck$384
- plus $2K from 33 others
Across 86 payments — averaging $3113.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$161K
- E.r. Squibb & Sons, L.L.C.$45K
- Incyte Corporation$31K
- Merck$17K
- Bristol Myers Squibb$14K
What the payments were for
- Consulting fees$12,36170%
- Travel & lodging$9275%
- Food & beverage$3,48720%
- Education$8745%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 11 | $7,294 |
| E.r. Squibb & Sons, L.L.C. | 23 | $2,955 |
| AstraZeneca | 21 | $2,441 |
| Novartis | 8 | $1,679 |
| Astellas Pharma US Inc | 14 | $620 |
| Merck | 25 | $384 |
| Bayer | 7 | $258 |
| Johnson & Johnson | 9 | $219 |
| Seagen Inc. | 2 | $211 |
| Amgen | 8 | $209 |
| Pfizer | 5 | $192 |
| Daiichi Sankyo Inc. | 9 | $158 |
| Bristol Myers Squibb | 6 | $115 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| GSK | 4 | $67 |
| Stemline Therapeutics Inc. | 4 | $64 |
| Karyopharm Therapeutics Inc. | 4 | $63 |
| Ipsen Biopharmaceuticals, Inc | 3 | $52 |
| Pharmaessentia USA Corporation | 2 | $50 |
| Gilead | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| AVEO Pharmaceuticals, Inc. | 2 | $41 |
| Taiho Oncology, Inc. | 2 | $38 |
| Eisai Inc. | 3 | $38 |
| Beone Medicines USA, Inc. | 2 | $37 |
| Servier Pharmaceuticals LLC | 2 | $33 |
| Genentech USA, Inc. | 2 | $32 |
| Beigene USA, Inc. | 2 | $30 |
| Pharmacosmos Therapeutics Inc. | 2 | $27 |
| Tactile Systems Technology Inc | 1 | $22 |
| Blue Earth Diagnostics | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Tesaro, Inc. | 1 | $19 |
| Partner Therapeutics, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Incyte Corporation | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,649 in reported general payments places this provider in the 80th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 49 | $812,765 |
| ImbruvicaIbrutinib | 26 | $358,063 |
| SprycelDasatinib | 21 | $331,452 |
| Lenalidomide | 24 | $309,800 |
| PomalystPomalidomide | 12 | $272,603 |
| BraftoviEncorafenib | 13 | $199,032 |
| VerzenioAbemaciclib | 12 | $184,214 |
| XtandiEnzalutamide | 11 | $145,262 |
| LonsurfTrifluridine/Tipiracil Hcl | 15 | $138,965 |
| Abiraterone Acetate | 15 | $37,267 |
| Imatinib Mesylate | 12 | $24,713 |
| XareltoRivaroxaban | 24 | $14,432 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 159 | $5,973 |
| Megestrol Acetate | 50 | $5,383 |
| Letrozole | 164 | $4,621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $115 | $812,76549 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst | $2,955 | $604,05533 claims |
| Astellas Pharma US IncXtandi | $620 | $145,26211 claims |
| Taiho Oncology, Inc.Lonsurf | $38 | $138,96515 claims |
| Johnson & JohnsonXarelto | $219 | $14,43224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Alexandria
- Bassam Abi-RachedAlexandria$13K
- Hana SafahBaton Rouge$2M
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Nakhle SabaBaton Rouge$842K
- Marc MatranaNew Orleans$757K
- Prakash PeddiShreveport$405K
- Sanjay JunejaBaton Rouge$346K
- Lingling duNew Orleans$173K
- Kamran ShahidLake Charles$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.